These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23470503)

  • 21. [Inflammatory bowel disease and lymphoproliferative disorders].
    Ye BD
    Korean J Gastroenterol; 2011 Oct; 58(4):171-7. PubMed ID: 22042416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma.
    Nissen LHC; Pierik M; Derikx LAAP; de Jong E; Kievit W; van den Heuvel TRA; van Rosendael AR; Plasmeijer EI; Dewint P; Verhoeven RHA; Overbeek LIH; Nagtegaal ID; Hoentjen F; van der Meulen-de Jong AE
    Inflamm Bowel Dis; 2017 Nov; 23(11):2018-2026. PubMed ID: 28837522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
    Subramaniam K; D'Rozario J; Pavli P
    J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.
    Calafat M; Mañosa M; Cañete F; Domènech E
    Drugs Aging; 2021 Mar; 38(3):193-203. PubMed ID: 33438138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Previous cancer and/or lymphoma in patients with refractory IBD--con: anti-TNF or conventional immunosuppressive treatment.
    Mantzaris GJ
    Dig Dis; 2014; 32 Suppl 1():122-7. PubMed ID: 25531364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
    Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
    J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of inflammatory bowel disease patients with a cancer history.
    Beaugerie L
    Curr Drug Targets; 2014; 15(11):1042-8. PubMed ID: 25146698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience.
    Madanchi M; Zeitz J; Barthel C; Samaras P; Scharl S; Sulz MC; Biedermann L; Frei P; Vavricka SR; Rogler G; Scharl M
    Digestion; 2016; 94(1):1-8. PubMed ID: 27318857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN.
    Atia O; Harel S; Ledderman N; Greenfeld S; Kariv R; Dotan I; Balicer R; Silverman B; Matz E; Levi Z; Waterman M; Fried I; Rowe JM; Turner D
    J Crohns Colitis; 2022 Jun; 16(5):786-795. PubMed ID: 34791097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era.
    Campos S; Portela F; Sousa P; Sofia C
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1313-9. PubMed ID: 27501126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
    Marzano AV; Borghi A; Meroni PL; Crosti C; Cugno M
    Autoimmunity; 2014 May; 47(3):146-53. PubMed ID: 24437626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases.
    Beaugerie L; Rahier JF; Kirchgesner J
    Clin Gastroenterol Hepatol; 2020 May; 18(6):1324-1335.e2. PubMed ID: 32059920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease].
    Kim JH; Kim JW
    Korean J Gastroenterol; 2017 Oct; 70(4):162-168. PubMed ID: 29060953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
    Jones JL; Loftus EV
    Inflamm Bowel Dis; 2007 Oct; 13(10):1299-307. PubMed ID: 17600819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a risk for lymphoma or extracolonic cancer in patients with inflammatory bowel disease?
    Toader E; Ciortescu I
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):368-74. PubMed ID: 24340518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.
    Clowry J; Sheridan J; Healy R; Deady S; Keegan D; Byrne K; Cullen G; Mulcahy H; Comber H; Parnell AC; Doherty G; Lally A
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):978-985. PubMed ID: 28045204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety profile of IBD: lymphoma risks.
    Bewtra M; Lewis JD
    Gastroenterol Clin North Am; 2009 Dec; 38(4):669-89. PubMed ID: 19913208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphoma in inflammatory bowel disease and treatment decisions.
    Bewtra M
    Am J Gastroenterol; 2012 Jul; 107(7):964-70. PubMed ID: 22764018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
    Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infectious and malignant complications of TNF inhibitor therapy in IBD.
    Targownik LE; Bernstein CN
    Am J Gastroenterol; 2013 Dec; 108(12):1835-42, quiz 1843. PubMed ID: 24042192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.